A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes.
Jacobo Pardo-Seco, Carmen Rodriguez-Tenreiro-Sánchez, Iago Giné-Vázquez et al.
✦ AI-curated · Sources linked
In 30 seconds
This Bayesian re-analysis examined hospitalization outcomes in the GALFLU randomized trial, which compared high-dose with standard-dose inactivated influenza vaccine in adults aged 65–79 years. The original trial found a lower incidence of hospitalization among participants assigned to high-dose vaccine. In the re-analysis, the estimated probability that high-dose vaccine provided benefit—defined as relative vaccine effectiveness greater than 10%—against influenza- or pneumonia-related hospitalization was greater than 80%. The abstract does not report the sample size or a specific effect estimate.
Key findings
- The Bayesian analysis estimated >80% probability of benefit, defined as relative vaccine effectiveness >10%, against influenza- or pneumonia-related hospitalization.
- The original trial reported lower hospitalization incidence with high-dose than standard-dose vaccine among adults aged 65–79 years.
Why it matters
Hospitalization is a clinically important outcome in older adults, and this re-analysis quantifies the probability that high-dose vaccination offers a meaningful advantage over standard-dose vaccination for influenza- or pneumonia-related admissions. The Bayesian estimate may help interpret the trial’s evidence, while remaining specific to the population and outcomes studied.
What to keep in mind
The abstract provides no sample size, numerical effect estimate, or uncertainty interval, limiting assessment of the precision and magnitude of the estimated benefit.